BCA-225 Breast carcinoma associated glycoprotein 225, or BCA-225, has been identified exclusively in breast cancers and certain adenocarcinomas, as one of the biomarkers. Unlike other identified proteins, monoclonal antibodies for BCA-225 (clonesCU18, CU26, and CU46) show no cross reactivity with lactating mammary glands and with gastrointestinal malignancies. This restricted distribution and frequency in breast carcinomas gives BCA-225 considerable clinical significanc in diagnosis and treatment of breast and other adenocarcinomas.
|Tissue Type/Cancer Type||
0.5 mL – Manual – Concentrate, 1 mL – Manual – Concentrate, 6 mL – Manual – RTU, 50 Tests – Automation – Xmatrx, 100 Tests – Automation – i6000, 160 Tests – Automation – Xmatrx, 5 slides – Xmatrx, 5 slides – Manual